Comparative lipid-lowering effects of policosanol and atorvastatin: A randomized, parallel, double-blind, placebo-controlled trial

American Heart Journal

Volumn 152, Issue 5, 2006, Pages 982.e1-982.e5

  Cubeddu, Luigi X ^a,b   Cubeddu, Roberto J ^a,b   Heimowitz, Todd ^a,b   Restrepo, Beatriz ^a,b   Lamas, Gervasio A ^a,b   Weinberg, Gloria B ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESSTOR; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPID LOWERING ACTIVITY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 33750407566     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.08.009     Document Type: Article

References (31)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Conti C.R. Evolution of NCEP guidelines: ATP1-ATPIII risk estimation for coronary heart disease in 2002. National Cholesterol Education Program. Clin Cardiol 25 (2002) 89-90
3. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
4. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of CAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
5. LIPID Investigators. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
6. Janikula M. Policosanol: a new treatment for cardiovascular disease?. Altern Med Rev 7 (2002) 203-217
7. Varady K.A., Wang Y., and Jones P.J. Role of policosanol in the prevention and treatment of cardiovascular disease. Nutr Rev 61 (2003) 376-383
8. Gouni-Berthold I., and Berthold H.K. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143 (2002) 356-364
9. Chen J.T., Wesley R., Shamburek R.D., et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 25 (2005) 171-183
10. Mesa A.R., Mas R., Noa M., et al. Toxicity of policosanol in beagle dogs: one-year study. Toxicol Lett 73 (1994) 81-90
11. Menendez R., Arruzazabala L., Mas R., et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 77 (1997) 923-932
12. Arruzazabala M.L., Molina V., Mas R., et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 29 (2002) 891-897
13. Mirkin A., Mas R., Martinto M., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 21 (2001) 31-41
14. Castano G., Mas R., Nordase M., et al. One-year study of the efficacy and safety of policosanol (5m twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res Clin Exp 56 (1995) 296-304
15. Crespo N., Alvarez, Mas R., et al. Effects of policosanol on patients with non-insulin dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res Clin Exp 58 (1997) 44-51
16. Torres O., Agramonte A., Illnait J., et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18 (1995) 393-397
17. Aneiros E., Calderon B., Mas R., et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res Clin Exp 54 (1993) 304-312
18. Pons P., Rodriguez M., Robaina C., et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 24 (1994) 27-33
19. Canetti M., Moreira M., Mas R., et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinemia. Int J Clin Pharmacol Res 15 (1995) 159-165
20. Pons S., Rodriguez M., Mas R., et al. One year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res 55 (1994) 1084-1092
21. Canetti M., Moreira M., Illnait J., et al. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia. Adv Ther 12 (1995) 245-254
22. Prat H., Roman O., and Pino E. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil 127 (1999) 286-294
23. Castano G., Mas R., Fernandez L., et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20 (2003) 153-163
24. Ortensi G., Gladstein J., Valli H., et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 58 (1997) 390-401
25. Illnait J., Castano G., Mas R., et al. A comparative study on the efficacy and tolerability of policosanol and simvastatin for treating type II hypercholesterolemia. Can J Cardiol 13 (1997) 342
26. Benitez M., Romero C., Mas R., et al. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 58 (1997) 859-867
27. Castano G., Mas R., Fernandez J.C., et al. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. Curr Ther Res Clin Exp 61 (2000) 137-146
28. Castano G., Mas R., Arruzazabala M., et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 29 (1999) 105-116
29. Lin Y., Rudrum M., et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 53 (2004) 1309-1314
30. Murphy K.J., Saint D.A., and Howe P.R. Lack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 13 Suppl (2004) S69
31. Wang Y.W., Jones P.J., Pischel I., et al. Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 38 (2003) 165-170